This prior work demonstrated that the NT1 fragment measured in CSF or blood discriminated AD and non-AD populations substantially better than full-length tau and tau measured via commonly used, mid-region directed antibodies alone. The gene discussed is MAPT; the disease is Alzheimer disease.